Bleselumab |
| Catalog No.GC72346 |
Bleselumab (ASKP 1240) is a human anti-CD40 monoclonal antibody (mAb).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1453067-91-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Bleselumab (0-1 μg/mL, 48 h) dose-depently inhibits PBMCs proliferation induced by soluble CD154[2].
Bleselumab (0.1-10 mg/kg, i.v.) inhibits Delayed-type hypersensitivity (DTH) reaction in cynomolgus monkeys[2].
Bleselumab (2 mg/kg, i.v.) prolongs renal allograft survival in Cynomolgus monkeys[3].
Bleselumab (2 or 5 mg/kg, i.v.) together with Tacrolimus shows a longer median survival time (MST) than monotherapy[3].
References:
[1]. Harland RC, et al. Efficacy and safety of bleselumab in kidney transplant recipients: A phase 2, randomized, open-label, noninferiority study. Am J Transplant. 2020 Jan;20(1):159-171.
[2]. Okimura K, et al. Characterization of ASKP1240, a fully human antibody targeting human CD40 with potent immunosuppressive effects. Am J Transplant. 2014 Jun;14(6):1290-9.
[3]. Song L, et al. Effects of ASKP1240 combined with tacrolimus or mycophenolate mofetil on renal allograft survival in Cynomolgus monkeys. Transplantation. 2014 Aug 15;98(3):267-76.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *